InSphero

Schlieren, Switzerland Founded: 2009 • Age: 17 yrs
Cell-based assays and 3D microtissues for drug screening are developed.
Request Access

About InSphero

InSphero is a company based in Schlieren (Switzerland) founded in 2009.. InSphero has raised $35.02 million across 10 funding rounds from investors including ZEISS, Zurcher Kantonalbank and European Union. InSphero offers products and services including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues. InSphero operates in a competitive market with competitors including Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others.

  • Headquarter Schlieren, Switzerland
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $35.02 M (USD)

    in 10 rounds

  • Latest Funding Round
  • Investors
    ZEISS

    & 7 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of InSphero

InSphero offers a comprehensive portfolio of products and services, including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables automated 3D cell culture for drug screening

Simulates human organs for advanced drug testing

Provides 3D liver models for toxicity and safety assessments

People of InSphero
Headcount 10-50
Employee Profiles 22
Employee Profiles
People
Lisa Hoelting
Senior Scientist | Deputy VP Technologies & Platforms
People
Madhu Lal Nag, MBS PhD
Chief Scientific Officer - Discovery
People
Nadia Carco
Executive Assistant to CEO & President
People
Bärbel Ulmer
Business Development Manager Europe

Unlock access to complete

Funding Insights of InSphero

InSphero has successfully raised a total of $35.02M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 10
  • Last Round
  • First Round

    (01 Jun 2009)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2023 Amount Series D - InSphero Valuation ZEISS
Jun, 2020 Amount Grant - InSphero Valuation

investors

Jan, 2020 Amount Grant - InSphero Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in InSphero

InSphero has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include ZEISS, Zurcher Kantonalbank and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Government agency and accelerator focusing on innovative startups and SMEs
Founded Year Domain Location
Startup acceleration programs are operated across sectors to support growth.
Founded Year Domain Location
Early-stage investments are directed toward ICT and health tech startups.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by InSphero

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - InSphero

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Insphero Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of InSphero

InSphero operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Induced pluripotent stem cell-derived organoid models are developed for research.
domain founded_year HQ Location
Regenerative medicine and 3D tissues are developed for therapeutic uses.
domain founded_year HQ Location
Developer of AI-based platform for lab-grown human tissues
domain founded_year HQ Location
Immune-competent human-derived models are developed for drug discovery applications.
domain founded_year HQ Location
Provider of computational tools for bacterial metabolomic and genomic data analysis
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about InSphero

When was InSphero founded?

InSphero was founded in 2009.

Where is InSphero located?

InSphero is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.

Is InSphero a funded company?

InSphero is a funded company, having raised a total of $35.02M across 10 funding rounds to date. The company's 1st funding round was a Grant of $56.09K, raised on Jun 01, 2009.

What does InSphero do?

InSphero was founded in 2009 in Schlieren, Switzerland, within the biotechnology sector. Organotypic 3D microtissues are produced for applications in biochemical compound screening and predictive drug testing. Services encompass compound toxicity testing, cell invasion assays, and interactions involving cells and extracellular matrices. Focus areas include metabolic diseases, oncology, and liver diseases, with offerings such as human prostate and mammary carcinoma, alongside rat liver microtissues.

Who are the top competitors of InSphero?

InSphero's top competitors include Newcells Biotech, Vivodyne and Parallel Bio.

What products or services does InSphero offer?

InSphero offers Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues.

Who are InSphero's investors?

InSphero has 8 investors. Key investors include ZEISS, Zurcher Kantonalbank, European Union, EIC Fund, and Jürg Gysi.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available